25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

INNO (InnoCan Pharma Corporation) Stock Analysis
Buy, Hold or Sell?

Let's analyze InnoCan Pharma Corporation together

I guess you are interested in InnoCan Pharma Corporation. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ InnoCan Pharma Corporationโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ InnoCan Pharma Corporationโ€™s Price Targets

I'm going to help you getting a better view of InnoCan Pharma Corporation. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about InnoCan Pharma Corporation

I send you an email if I find something interesting about InnoCan Pharma Corporation.

1. Quick Overview

1.1. Quick analysis of InnoCan Pharma Corporation (30 sec.)










1.2. What can you expect buying and holding a share of InnoCan Pharma Corporation? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$0.03
Expected worth in 1 year
C$0.04
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
C$0.01
Return On Investment
4.9%

For what price can you sell your share?

Current Price per Share
C$0.21
Expected price per share
C$0.21 - C$0.24
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of InnoCan Pharma Corporation (5 min.)




Live pricePrice per Share (EOD)
C$0.21
Intrinsic Value Per Share
C$0.31 - C$0.38
Total Value Per Share
C$0.34 - C$0.41

2.2. Growth of InnoCan Pharma Corporation (5 min.)




Is InnoCan Pharma Corporation growing?

Current yearPrevious yearGrowGrow %
How rich?$6.8m$4.6m$2m30.9%

How much money is InnoCan Pharma Corporation making?

Current yearPrevious yearGrowGrow %
Making money-$162.2k-$1.2m$1.1m700.8%
Net Profit Margin-2.3%-27.6%--

How much money comes from the company's main activities?

2.3. Financial Health of InnoCan Pharma Corporation (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of InnoCan Pharma Corporation?

Welcome investor! InnoCan Pharma Corporation's management wants to use your money to grow the business. In return you get a share of InnoCan Pharma Corporation.

First you should know what it really means to hold a share of InnoCan Pharma Corporation. And how you can make/lose money.

Speculation

The Price per Share of InnoCan Pharma Corporation is C$0.21. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of InnoCan Pharma Corporation.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in InnoCan Pharma Corporation, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$0.03. Based on the TTM, the Book Value Change Per Share is C$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of InnoCan Pharma Corporation.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.00-0.9%0.00-0.3%0.00-2.1%0.00-1.2%0.00-2.4%0.00-2.1%
Usd Book Value Change Per Share0.00-0.2%0.000.9%0.00-0.3%0.00-0.3%0.000.5%0.000.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.2%0.000.9%0.00-0.3%0.00-0.3%0.000.5%0.000.5%
Usd Price Per Share0.15-0.16-0.22-0.20-0.27-0.26-
Price to Earnings Ratio-18.81--30.18--15.62--28.05--25.96--23.60-
Price-to-Total Gains Ratio-326.83-80.22--169.65-2.28--5.88--7.89-
Price to Book Ratio6.36-7.12-13.88-10.44-21.11-20.75-
Price-to-Total Gains Ratio-326.83-80.22--169.65-2.28--5.88--7.89-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.153426
Number of shares6517
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (6517 shares)12.156.28
Gains per Year (6517 shares)48.6125.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10493902515
20978805040
3014613707565
40194186010090
502432350126115
602922840151140
703403330176165
803893820201190
904374310226215
1004864800251240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.020.00.09.1%2.020.00.09.1%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%10.010.00.050.0%11.011.00.050.0%11.011.00.050.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%10.010.00.050.0%11.011.00.050.0%11.011.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of InnoCan Pharma Corporation compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0010.003-125%-0.001+18%-0.001+15%0.001-148%0.001-143%
Book Value Per Share--0.0320.031+2%0.022+48%0.028+16%0.022+45%0.021+56%
Current Ratio--4.0773.738+9%3.549+15%4.723-14%3.655+12%3.593+13%
Debt To Asset Ratio--0.3630.297+22%0.336+8%0.265+37%0.441-18%0.434-16%
Debt To Equity Ratio--0.8400.586+43%0.602+40%0.460+83%0.965-13%0.932-10%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--54568084.80061129518.800-11%84251643.400-35%78939033.000-31%105390347.480-48%98631880.073-45%
Eps---0.003-0.001-72%-0.006+123%-0.003+26%-0.007+150%-0.006+123%
Ev To Sales Ratio--1.2781.509-15%3.479-63%10.487-88%380.170-100%380.170-100%
Free Cash Flow Per Share--0.002-0.001+133%-0.004+342%-0.004+322%-0.005+386%-0.005+384%
Free Cash Flow To Equity Per Share--0.0060.002+207%0.001+987%-0.001+120%0.001+450%0.001+601%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.382----------
Intrinsic Value_10Y_min--0.312----------
Intrinsic Value_1Y_max---0.007----------
Intrinsic Value_1Y_min---0.007----------
Intrinsic Value_3Y_max--0.013----------
Intrinsic Value_3Y_min--0.011----------
Intrinsic Value_5Y_max--0.075----------
Intrinsic Value_5Y_min--0.066----------
Market Cap61408200.000+2%59946100.00065063450.000-8%87726000.000-32%81999441.667-27%109291975.000-45%102280540.909-41%
Net Profit Margin---0.075-0.023-70%-0.276+270%-0.623+735%-52.056+69630%-47.324+63291%
Operating Margin----0%-0.0350%-0.5270%-21.7010%-19.7280%
Operating Ratio--1.0251.112-8%1.321-22%1.916-47%22.334-95%20.304-95%
Pb Ratio6.513+2%6.3587.123-11%13.879-54%10.442-39%21.105-70%20.751-69%
Pe Ratio-19.271-2%-18.812-30.181+60%-15.623-17%-28.054+49%-25.956+38%-23.604+25%
Price Per Share0.210+2%0.2050.223-8%0.300-32%0.280-27%0.374-45%0.350-41%
Price To Free Cash Flow Ratio30.897+2%30.1623.845+684%-19.413+164%-9.056+130%-14.033+147%-12.925+143%
Price To Total Gains Ratio-334.797-2%-326.82680.217-507%-169.648-48%2.283-14416%-5.880-98%-7.887-98%
Quick Ratio---0.002-100%0.134-100%0.071-100%0.095-100%0.152-100%
Return On Assets---0.054-0.014-73%-0.177+228%-0.112+107%-0.272+405%-0.240+346%
Return On Equity---0.124-0.033-73%-0.305+145%-0.169+36%-0.604+386%-0.532+328%
Total Gains Per Share---0.0010.003-125%-0.001+18%-0.001+15%0.001-148%0.001-143%
Usd Book Value--6888311.8896723304.417+2%4648960.495+48%5955602.991+16%4736464.457+45%4427064.085+56%
Usd Book Value Change Per Share--0.0000.002-125%-0.001+18%-0.001+15%0.001-148%0.001-143%
Usd Book Value Per Share--0.0240.023+2%0.016+48%0.020+16%0.016+45%0.015+56%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--39867442.75544661226.435-11%61554250.668-35%57672857.510-31%76998187.869-48%72060451.581-45%
Usd Eps---0.002-0.001-72%-0.004+123%-0.003+26%-0.005+150%-0.004+123%
Usd Free Cash Flow--363016.437-120505.456+133%-877539.733+342%-807119.878+322%-1038147.005+386%-983271.793+371%
Usd Free Cash Flow Per Share--0.0010.000+133%-0.003+342%-0.003+322%-0.004+386%-0.004+384%
Usd Free Cash Flow To Equity Per Share--0.0050.002+207%0.000+987%-0.001+120%0.001+450%0.001+601%
Usd Market Cap44864830.920+2%43796620.66047535356.570-8%64092615.600-32%59908792.082-27%79848716.935-45%74726163.188-41%
Usd Price Per Share0.153+2%0.1500.163-8%0.219-32%0.205-27%0.273-45%0.256-41%
Usd Profit---582026.353-162257.347-72%-1299308.830+123%-852288.590+46%-1527219.149+162%-1362243.498+134%
Usd Revenue--7796353.0037616594.864+2%4716463.552+65%4432617.366+76%2682771.470+191%2438883.155+220%
Usd Total Gains Per Share--0.0000.002-125%-0.001+18%-0.001+15%0.001-148%0.001-143%
 EOD+4 -4MRQTTM+13 -22YOY+24 -113Y+22 -135Y+21 -1410Y+21 -14

3.3 Fundamental Score

Let's check the fundamental score of InnoCan Pharma Corporation based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.271
Price to Book Ratio (EOD)Between0-16.513
Net Profit Margin (MRQ)Greater than0-0.075
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than14.077
Debt to Asset Ratio (MRQ)Less than10.363
Debt to Equity Ratio (MRQ)Less than10.840
Return on Equity (MRQ)Greater than0.15-0.124
Return on Assets (MRQ)Greater than0.05-0.054
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of InnoCan Pharma Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.254
Ma 20Greater thanMa 500.214
Ma 50Greater thanMa 1000.186
Ma 100Greater thanMa 2000.188
OpenGreater thanClose0.210
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About InnoCan Pharma Corporation

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company was incorporated in 2018 and is headquartered in Calgary, Canada.

Fundamental data was last updated by Penke on 2025-07-07 05:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย InnoCan Pharma Corporation earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -7.5%ย means thatย $-0.07 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of InnoCan Pharma Corporation:

  • The MRQ is -7.5%. The company is making a loss. -1
  • The TTM is -2.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-7.5%TTM-2.3%-5.2%
TTM-2.3%YOY-27.6%+25.4%
TTM-2.3%5Y-5,205.6%+5,203.3%
5Y-5,205.6%10Y-4,732.4%-473.2%
4.3.1.2. Return on Assets

Shows howย efficientย InnoCan Pharma Corporation is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • -5.4% Return on Assets means thatย InnoCan Pharma Corporation generatedย $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of InnoCan Pharma Corporation:

  • The MRQ is -5.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.4%TTM-1.4%-3.9%
TTM-1.4%YOY-17.7%+16.2%
TTM-1.4%5Y-27.2%+25.8%
5Y-27.2%10Y-24.0%-3.2%
4.3.1.3. Return on Equity

Shows how efficient InnoCan Pharma Corporation is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • -12.4% Return on Equity means InnoCan Pharma Corporation generated $-0.12ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of InnoCan Pharma Corporation:

  • The MRQ is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-3.3%-9.1%
TTM-3.3%YOY-30.5%+27.2%
TTM-3.3%5Y-60.4%+57.1%
5Y-60.4%10Y-53.2%-7.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of InnoCan Pharma Corporation.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient InnoCan Pharma Corporation is operatingย .

  • Measures how much profit InnoCan Pharma Corporation makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%ย means the company generated $0.00 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of InnoCan Pharma Corporation:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3.5%+3.5%
TTM-5Y-2,170.1%+2,170.1%
5Y-2,170.1%10Y-1,972.8%-197.3%
4.3.2.2. Operating Ratio

Measures how efficient InnoCan Pharma Corporation is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.02 means that the operating costs are $1.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of InnoCan Pharma Corporation:

  • The MRQ is 1.025. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.112. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.025TTM1.112-0.088
TTM1.112YOY1.321-0.209
TTM1.1125Y22.334-21.222
5Y22.33410Y20.304+2.030
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of InnoCan Pharma Corporation.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if InnoCan Pharma Corporation is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.08ย means the company has $4.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of InnoCan Pharma Corporation:

  • The MRQ is 4.077. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.738. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.077TTM3.738+0.338
TTM3.738YOY3.549+0.189
TTM3.7385Y3.655+0.083
5Y3.65510Y3.593+0.062
4.4.3.2. Quick Ratio

Measures if InnoCan Pharma Corporation is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.00ย means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of InnoCan Pharma Corporation:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.002-0.002
TTM0.002YOY0.134-0.132
TTM0.0025Y0.095-0.093
5Y0.09510Y0.152-0.057
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of InnoCan Pharma Corporation.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of InnoCan Pharma Corporationย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย InnoCan Pharma Corporation to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.36ย means that InnoCan Pharma Corporation assets areย financed with 36.3% credit (debt) and the remaining percentage (100% - 36.3%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of InnoCan Pharma Corporation:

  • The MRQ is 0.363. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.297. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.363TTM0.297+0.066
TTM0.297YOY0.336-0.039
TTM0.2975Y0.441-0.144
5Y0.44110Y0.434+0.007
4.5.4.2. Debt to Equity Ratio

Measures ifย InnoCan Pharma Corporation is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 84.0% means that company has $0.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of InnoCan Pharma Corporation:

  • The MRQ is 0.840. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.586. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.840TTM0.586+0.254
TTM0.586YOY0.602-0.016
TTM0.5865Y0.965-0.380
5Y0.96510Y0.932+0.033
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings InnoCan Pharma Corporation generates.

  • Above 15 is considered overpriced butย always compareย InnoCan Pharma Corporation to theย Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -18.81 means the investor is paying $-18.81ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of InnoCan Pharma Corporation:

  • The EOD is -19.271. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.812. Based on the earnings, the company is expensive. -2
  • The TTM is -30.181. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.271MRQ-18.812-0.459
MRQ-18.812TTM-30.181+11.369
TTM-30.181YOY-15.623-14.558
TTM-30.1815Y-25.956-4.225
5Y-25.95610Y-23.604-2.353
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of InnoCan Pharma Corporation:

  • The EOD is 30.897. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 30.162. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 3.845. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD30.897MRQ30.162+0.736
MRQ30.162TTM3.845+26.316
TTM3.845YOY-19.413+23.259
TTM3.8455Y-14.033+17.878
5Y-14.03310Y-12.925-1.108
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย InnoCan Pharma Corporation is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 6.36 means the investor is paying $6.36ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of InnoCan Pharma Corporation:

  • The EOD is 6.513. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.358. Based on the equity, the company is overpriced. -1
  • The TTM is 7.123. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.513MRQ6.358+0.155
MRQ6.358TTM7.123-0.764
TTM7.123YOY13.879-6.756
TTM7.1235Y21.105-13.983
5Y21.10510Y20.751+0.354
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets10,817
Total Liabilities3,929
Total Stockholder Equity4,680
 As reported
Total Liabilities 3,929
Total Stockholder Equity+ 4,680
Total Assets = 10,817

Assets

Total Assets10,817
Total Current Assets10,710
Long-term Assets107
Total Current Assets
Cash And Cash Equivalents 6,365
Inventory 2,954
Other Current Assets 169
Total Current Assets  (as reported)10,710
Total Current Assets  (calculated)9,488
+/- 1,222
Long-term Assets
Property Plant Equipment 107
Long-term Assets  (as reported)107
Long-term Assets  (calculated)107
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,627
Long-term Liabilities1,302
Total Stockholder Equity4,680
Total Current Liabilities
Accounts payable 178
Other Current Liabilities 1,729
Total Current Liabilities  (as reported)2,627
Total Current Liabilities  (calculated)1,907
+/- 720
Long-term Liabilities
Long term Debt 1,302
Long-term Liabilities  (as reported)1,302
Long-term Liabilities  (calculated)1,302
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)4,680
Total Stockholder Equity (calculated)0
+/- 4,680
Other
Common Stock Shares Outstanding 291,227
Net Invested Capital 5,982
Net Working Capital 8,083
Property Plant and Equipment Gross 107



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
2,582
1,719
3,933
2,792
4,334
5,686
5,715
7,120
12,575
11,284
9,468
8,316
6,976
6,398
5,902
6,866
6,940
9,040
8,716
9,595
9,260
10,817
10,8179,2609,5958,7169,0406,9406,8665,9026,3986,9768,3169,46811,28412,5757,1205,7155,6864,3342,7923,9331,7192,582
   > Total Current Assets 
2,487
1,634
3,858
2,727
4,278
5,641
5,680
7,055
12,521
11,195
9,388
8,223
6,878
6,257
5,760
6,732
6,804
8,912
8,594
9,477
9,147
10,710
10,7109,1479,4778,5948,9126,8046,7325,7606,2576,8788,2239,38811,19512,5217,0555,6805,6414,2782,7273,8581,6342,487
       Cash And Cash Equivalents 
1,973
1,027
3,303
1,787
2,338
4,397
4,644
5,866
11,048
9,547
7,726
6,416
4,947
4,089
3,373
4,024
3,885
4,595
5,189
5,057
5,008
6,365
6,3655,0085,0575,1894,5953,8854,0243,3734,0894,9476,4167,7269,54711,0485,8664,6444,3972,3381,7873,3031,0271,973
       Net Receivables 
57
607
555
940
1,129
169
101
130
169
172
249
170
15
15
451
21
17
16
18
0
0
0
0001816172145115151702491721691301011691,12994055560757
       Other Current Assets 
31
0
0
0
72
376
62
77
79
101
109
105
0
0
102
0
0
0
35
35
150
169
1691503535000102001051091017977623767200031
   > Long-term Assets 
95
85
75
65
56
45
35
65
54
89
80
93
98
141
142
134
136
128
122
118
113
107
10711311812212813613414214198938089546535455665758595
       Property Plant Equipment 
95
85
75
65
56
45
35
65
54
89
80
93
98
141
142
134
136
128
122
118
113
107
10711311812212813613414214198938089546535455665758595
> Total Liabilities 
1,169
466
2,067
2,313
7,941
4,533
4,053
3,167
3,564
2,540
2,316
1,055
751
1,059
899
2,367
2,554
4,333
2,675
2,654
2,238
3,929
3,9292,2382,6542,6754,3332,5542,3678991,0597511,0552,3162,5403,5643,1674,0534,5337,9412,3132,0674661,169
   > Total Current Liabilities 
1,131
436
2,047
2,303
7,940
4,533
4,053
3,167
3,564
2,526
2,304
1,030
731
1,033
873
2,351
2,543
4,326
2,671
2,653
2,238
2,627
2,6272,2382,6532,6714,3262,5432,3518731,0337311,0302,3042,5263,5643,1674,0534,5337,9402,3032,0474361,131
       Accounts payable 
27
16
120
432
527
148
340
86
53
154
248
139
95
289
177
333
112
477
389
132
185
178
1781851323894771123331772899513924815453863401485274321201627
       Other Current Liabilities 
661
420
1,927
1,871
6,992
4,385
3,713
3,081
3,078
2,372
2,056
891
304
386
696
1,672
1,946
2,740
1,683
1,813
1,565
1,729
1,7291,5651,8131,6832,7401,9461,6726963863048912,0562,3723,0783,0813,7134,3856,9921,8711,927420661
   > Long-term Liabilities 
38
30
20
10
1
0
0
0
0
14
12
25
20
26
26
16
11
7
4
1
0
1,302
1,302014711162626202512140000110203038
       Capital Lease Obligations Min Short Term Debt
72
30
20
10
38
0
0
0
1
14
12
25
34
26
26
16
33
7
4
1
10
0
010147331626263425121410003810203072
> Total Stockholder Equity
1,413
1,253
1,866
479
-3,607
1,153
1,662
3,964
9,055
8,866
7,365
7,467
6,394
5,466
5,007
4,303
4,103
4,111
4,826
5,152
5,167
4,680
4,6805,1675,1524,8264,1114,1034,3035,0075,4666,3947,4677,3658,8669,0553,9641,6621,153-3,6074791,8661,2531,413
   Common Stock0000000000000000000000
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 0000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue29,437
Cost of Revenue-3,250
Gross Profit26,18726,187
 
Operating Income (+$)
Gross Profit26,187
Operating Expense-30,684
Operating Income-1,247-4,497
 
Operating Expense (+$)
Research Development1,549
Selling General Administrative25,885
Selling And Marketing Expenses-
Operating Expense30,68427,434
 
Net Interest Income (+$)
Interest Income0
Interest Expense-7
Other Finance Cost-0
Net Interest Income-7
 
Pretax Income (+$)
Operating Income-1,247
Net Interest Income-7
Other Non-Operating Income Expenses-
Income Before Tax (EBT)919-3,420
EBIT - interestExpense = -7
-1,834
-1,827
Interest Expense7
Earnings Before Interest and Taxes (EBIT)-926
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax919
Tax Provision-1,181
Net Income From Continuing Ops-262-262
Net Income-1,834
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net2,1737
 

Technical Analysis of InnoCan Pharma Corporation
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of InnoCan Pharma Corporation. The general trend of InnoCan Pharma Corporation is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine InnoCan Pharma Corporation's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. InnoCan Pharma Corporation Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of InnoCan Pharma Corporation.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.24 < 0.24 < 0.24.

The bearish price targets are: 0.21 > 0.21 > 0.21.

Know someone who trades $INNO? Share this with them.๐Ÿ‘‡

InnoCan Pharma Corporation Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of InnoCan Pharma Corporation. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

InnoCan Pharma Corporation Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of InnoCan Pharma Corporation. The current macd is 0.00919751.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the InnoCan Pharma Corporation price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for InnoCan Pharma Corporation. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the InnoCan Pharma Corporation price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
InnoCan Pharma Corporation Daily Moving Average Convergence/Divergence (MACD) ChartInnoCan Pharma Corporation Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of InnoCan Pharma Corporation. The current adx is 20.99.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell InnoCan Pharma Corporation shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
InnoCan Pharma Corporation Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of InnoCan Pharma Corporation. The current sar is 0.23764768.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
InnoCan Pharma Corporation Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of InnoCan Pharma Corporation. The current rsi is 52.25. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
InnoCan Pharma Corporation Daily Relative Strength Index (RSI) ChartInnoCan Pharma Corporation Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of InnoCan Pharma Corporation. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the InnoCan Pharma Corporation price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
InnoCan Pharma Corporation Daily Stochastic Oscillator ChartInnoCan Pharma Corporation Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of InnoCan Pharma Corporation. The current cci is -9.10530483.

InnoCan Pharma Corporation Daily Commodity Channel Index (CCI) ChartInnoCan Pharma Corporation Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of InnoCan Pharma Corporation. The current cmo is -4.87569398.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
InnoCan Pharma Corporation Daily Chande Momentum Oscillator (CMO) ChartInnoCan Pharma Corporation Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of InnoCan Pharma Corporation. The current willr is -75.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that InnoCan Pharma Corporation is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
InnoCan Pharma Corporation Daily Williams %R ChartInnoCan Pharma Corporation Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of InnoCan Pharma Corporation.

InnoCan Pharma Corporation Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of InnoCan Pharma Corporation. The current atr is 0.01145035.

InnoCan Pharma Corporation Daily Average True Range (ATR) ChartInnoCan Pharma Corporation Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of InnoCan Pharma Corporation. The current obv is 7,072,041.

InnoCan Pharma Corporation Daily On-Balance Volume (OBV) ChartInnoCan Pharma Corporation Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of InnoCan Pharma Corporation. The current mfi is 75.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
InnoCan Pharma Corporation Daily Money Flow Index (MFI) ChartInnoCan Pharma Corporation Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for InnoCan Pharma Corporation.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

InnoCan Pharma Corporation Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of InnoCan Pharma Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.254
Ma 20Greater thanMa 500.214
Ma 50Greater thanMa 1000.186
Ma 100Greater thanMa 2000.188
OpenGreater thanClose0.210
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of InnoCan Pharma Corporation with someone you think should read this too:
  • Are you bullish or bearish on InnoCan Pharma Corporation? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about InnoCan Pharma Corporation? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about InnoCan Pharma Corporation

I send you an email if I find something interesting about InnoCan Pharma Corporation.


Comments

How you think about this?

Leave a comment

Stay informed about InnoCan Pharma Corporation.

Receive notifications about InnoCan Pharma Corporation in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.